Generic versions of antiretrovirals, or ARVs, that cost a fraction of the price of brand medicines make it possible for MSF to treat 160,000 people living with HIV around the world. Eighty percent of the ARVs we use come from India, and millions of others in developing countries depend on India-made generics as well.
But the European Commission has begun directing its trade policies in a way that could stamp out the production of lifesaving generics in India. MSF has launched a global public campaign to tell Europe to back off, and to honor its commitments to global health.
